India Makes Major Push To Stem Increase In MDR-TB Risk
This article was originally published in PharmAsia News
India plans to provide diagnostics equipment and treatments in an effort to meet a target of getting control by 2010 of multi-drug resistant tuberculosis in the country. The TB type is resistant to isoniazid and rifampicin, the best first-line drugs for fighting the disease. The rate of MDR-TB cases in India is not necessarily increasing any faster than in other developing countries, but is considered more troublesome in the country because of its huge population. (Click here for more
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.